A Novel Approach to Cancer-Agnostic Treatment of Tumors With Non-Genetically Modified Macrophages

Time: 2:00 pm
day: Day One Track A PM


  • SIRpant uses a non-genetic approach to reprogramming macrophages that removes SIRPɑ and simultaneously reprograms them to promote an anti-cancer response whilst reducing manufacturing time 
  • Our macrophages act by directly attacking cancerous cells, stimulating cancer neoantigen-specific cytotoxic T cells and antibodies, reducing immunosuppressive elements, and perpetuating a pro-inflammatory TME that favors cancer elimination 
  • Overcoming manufacturing challenges in the difficult transition from bench to clinic and setting up a Phase 1 study